Related Experiment Video

Updated: May 1, 2026

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence
10:09

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

7.7K

bHLH Transcription factors inhibitors for cancer therapy: general features for in silico drug design

I F Tsigelny, V L Kouznetsova, S C Pingle

  • 1UCSD San Diego Supercomputer Center, 9500 Gilman Drive, La Jolla, CA 92093-0505, USA. itsigeln@ucsd.edu.

Current Medicinal Chemistry
|April 17, 2014
PubMed

Insights

Basic-helix-loop-helix (bHLH) transcription factors are crucial in cancer. Understanding their shared structural features, like complementary residues for dimerization and DNA binding, enables the in silico design of novel cancer therapeutics targeting these proteins.

Area of Science:

  • Molecular Biology
  • Biochemistry
  • Cancer Research

Background:

  • Basic-helix-loop-helix (bHLH) transcription factors (TFs) are implicated in tumor development and progression.
  • Current therapeutic strategies focus on inhibiting TF dimerization or DNA binding.

Purpose of the Study:

  • To elucidate common structural features of bHLH TFs for therapeutic targeting.
  • To establish a conceptual framework for the in silico design of bHLH TF inhibitors.

Main Methods:

  • Analysis of conserved residues in functionally important regions of bHLH TFs.
  • Identification of complementary hydrophobic, anionic, and cationic residues involved in dimerization.
  • Characterization of positively charged residues critical for DNA interaction.

Main Results:

  • bHLH TFs exhibit striking similarities in dimerization interfaces, featuring complementary hydrophobic and charged residues.
  • Specific positively charged residues on the TF surface are conserved for DNA binding.
  • These conserved features provide a basis for rational inhibitor design.

Conclusions:

  • The conserved structural complementarity in bHLH TFs offers a unified strategy for inhibitor development.
  • In silico design approaches can be employed to create targeted inhibitors for cancer-related bHLH TFs.
  • This research opens avenues for novel therapeutic interventions in oncology.

More Related Videos

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

10.9K
Protein WISDOM: A Workbench for In silico De novo Design of BioMolecules10:58

Protein WISDOM: A Workbench for In silico De novo Design of BioMolecules

Published on: July 25, 2013

16.2K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

4.3K
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
8.3K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
4.4K